Navigation Links
More cutting-edge cancer research supported by industry
Date:5/17/2012

CHICAGO, IL (May 16, 2012)Nearly half of the research presented at ASCO's annual meeting last year came from researchers with ties to companies, and the amount appears to be increasing every year, according to new findings from Fox Chase Cancer Center. The new findings will be presented this year at the 2012 American Society of Clinical Oncology Annual Meeting on Monday, June 4.

"The results suggest that there may be an increasing dependence on industry to support cancer research," says study author Angela R. Bradbury, M.D., assistant professor in the Department of Clinical Genetics at Fox Chase. "This doesn't mean the research is flawed or biased in any way," she cautions, "but it does mean that the professional and research community has to investigate the impact of these relationships and find ways to manage any potential conflicts of interest."

Bradbury and her colleagues reviewed research submitted to the 2011 American Society of Clinical Oncology Annual Meeting, which requires all authors who want to present their findings to state if they have any relationships with industry. This includes being employed by a company, as well as owning stock, serving as a consultant or expert witness, and receiving honoraria for giving talks or participating in research projects.

They found that 48% of research accepted for presentation at the meeting in 2011 came from a group where at least one author had a relationship to industryup from 39% of research presented in 2006. These ties to industry appeared to increase every year.

Interestingly, in a second related abstract by the same authors, Beverly Moy, M.D., M.P.H., clinical director of the Breast Oncology Program and a medical oncologist at the Massachusetts General Hospital, reported that high profile researchselected to be presented more prominently at the meetingwas more likely to come from scientists with relationships to industry. Studies from authors with ties to industry also tended to receive higher scores from their peers.

"This finding doesn't mean that researchers with industry have some 'in' that others don't," says Bradbury. "Rather, it suggests that authors of much of the cutting-edge, clinically important research have relationships with industry."

This is not a surprise, she says, given that other sources of research funding have dried up recently. "We need money for cancer research, and it has to come from somewhere. The government has had to cut back on its support, and with the economic crisis research foundations have less money to allocate as well."

But if cancer researchers are going to continue to link up with companies that can profit from their data, the community has to be aware of the potential issues, Bradbury cautions. "If we're going to have relationships with industry, we're going to have to find ways to monitor and manage these relationships, to ensure they don't end up biasing any results."

Given that many great clinicians work with companies, patients shouldn't worry about asking their doctors if they personally have ties to industry, Bradbury reassures. "Whether or not a doctor has a relationship with a company shouldn't have any impact on patient care," she says.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Conference: Improving K-12 education with cutting-edge cognitive neuroscience research
2. AGA presents cutting-edge research during DDW
3. Cutting-edge salivary diagnostics research presented at AADR 3rd Fall Focused Symposium
4. From cholera to blindness, experts present cutting-edge research at international meeting
5. New book offers cutting-edge perspective on causes of schizophrenia; related disorders
6. AGA presents cutting-edge research during DDW
7. Singapore Performs Cutting-edge Eye Surgeries
8. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
9. Researchers undertake radical new cancer survivorship study
10. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
11. Advanced Prostate Cancer Drug May Help at Earlier Stage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... The threat ... went to work for a company involved in the underground testing of nuclear weapons. ... “Dying for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the ...
(Date:2/27/2017)... ... , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and ... for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss ... compiled into a single volume a compelling argument that the disease does exist in ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five ... genders. And the need for advanced services is growing. , Project WE vs ... program, in collaboration with their non-profit partners in their fight against cancer and in ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC ... North America, today announced it would be offering some it’s exclusive product line ... on crafting quality and unique baby clothing/feeding products, will team up with AMAZON ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... (PD) in persons with a specific LRRK2 mutation, according to a study released ... studies have provided evidence of a link between pesticides and incidence of sporadic ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
Breaking Medicine Technology: